Dilon Helps Shape the Future of Breast Cancer Care during Inaugural ASBrS 2025 Forum on Breast Surgery Partnering to Create Value and Innovation

By Dec 26, 2018 News

The American Society of Breast Surgeons (ASBrS) hosted its first 2025 Forum on Breast Surgery on October 20 in Hanover, Maryland. This forum united thought leaders, payment and reimbursement experts, and Industry Relations Council members to develop a strategic approach to prepare its physician members to lead enhancements in breast cancer surgery, therapeutics and technology for the future.

“When physicians, societies and industry develop partnerships, patients win,” explained Dr. Susan Boolbol, Corporate Relations Committee Chair for ASBrS. “At American Society of Breast Surgeons, it is our goal to continue to partner with companies such as Dilon who have a vision and drive to make that vision a reality through advances in technology. By working together, we can ultimately make great advances for our patients.”

Dilon was honored to be one of 10 companies afforded the privilege of attending this inaugural meeting and engaging with ASBrS leadership, and other industry leaders in a dynamic and provocative discussion, exploring the evolving role of the breast surgeon and innovation in a dynamic, value-driven, economic environment.

“We recognize the importance in positively creating change to deliver quality care for breast cancer patients, and are fully aligned with ASBrS’s vision of partnering across multiple stakeholders to define the future,” said Susan Turner, Dilon VP of Healthcare Economics & Reimbursement.

Dilon has already demonstrated an improvement in the care of breast cancer patients utilizing our revolutionary Radiofrequency Spectroscopy Technology in the MarginProbe device. MarginProbe has been used in over 16,000 surgeries in the US, Israel and the UK and in 10 peer-reviewed publications, two randomized controlled trials and 35 abstracts. The device has demonstrated a reduction in the second surgery rate of breast-conserving surgeries up to 79%. Identifying the positive margins is important for physicians as the risk of recurrence is significantly increased when microscopic residual cancer is left behind. With the introduction of MarginProbe, Dune is leading the movement from volume-based to value-based healthcare in breast conservation surgery. This forum emphasized the necessity of innovation in rapidly moving breast care toward minimally invasive treatment options. Dune’s RF Spectroscopy technology, specifically its next generation of miniaturized sensors and smart biopsy guidance, funded through the Horizon 2020 program is poised to disrupt the current treatment paradigms.

ASBrS 2025 Forum included relevant data, panel discussions, and small group conversations around important topics that will prepare Society members and industry partners for evolution and changing dynamic of breast cancer care. Such topics included a review of expected coding changes per the 2019 Final Rule and their possible impact to healthcare delivery, the challenge of incorporating innovation in the era of value-based payments and risk-sharing, and how physicians and industry can remain relevant in the rapidly evolving landscape of breast disease. The group collaborated to define shared goals and strategies for improving breast care through education, quality improvement and research, with a long-term vision of continued partnership to solve for challenges by leading innovative solutions. Efforts are underway to use the meeting learnings to develop future Society-to-industry and industry-to-industry initiatives. This includes multi-stakeholder symposia focusing on areas of interest such as non-surgical breast cancer treatment. Dune looks forward to continued engagement with ASBrS and industry partners, building on the collaboration and momentum initiated at the 2025 Forum.

To learn more about the ways in which Dilon improves breast cancer patients’ overall quality of care and satisfaction through our MarginProbe technology, please contact us at info@dunemedical.com.